APA (7th ed.) Citation

L, B., A, C., ML, C., MR, P., L, P., E, S., & C, D. F. (2024). Vemurafenib combined with cytarabine and cladribine results in clinical efficacy but persistent BRAFV600E clone in a newborn affected by high-risk Langerhans cell histiocytosis. British journal of haematology, 205(3), 1234. https://doi.org/10.1111/bjh.19637

Chicago Style (17th ed.) Citation

L, Beneforti, Chinnici A, Coniglio ML, Papa MR, Punzi L, Sieni E, and De Fusco C. "Vemurafenib Combined with Cytarabine and Cladribine Results in Clinical Efficacy but Persistent BRAFV600E Clone in a Newborn Affected by High-risk Langerhans Cell Histiocytosis." British Journal of Haematology 205, no. 3 (2024): 1234. https://doi.org/10.1111/bjh.19637.

MLA (9th ed.) Citation

L, Beneforti, et al. "Vemurafenib Combined with Cytarabine and Cladribine Results in Clinical Efficacy but Persistent BRAFV600E Clone in a Newborn Affected by High-risk Langerhans Cell Histiocytosis." British Journal of Haematology, vol. 205, no. 3, 2024, p. 1234, https://doi.org/10.1111/bjh.19637.